New asthma drug enters early human testing

NCT ID NCT06920901

Ongoing Symptom relief Sponsor: Apogee Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug called APG777 in 31 adults with mild-to-moderate asthma. The main goal is to check if the drug is safe and how the body handles it. Participants receive either the drug or a placebo, and researchers monitor for side effects and measure drug levels in the blood over about a year.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA

Contacts and locations

Locations

Investigational Site

La Jolla, California, 92037, United States
Investigational Site

Long Beach, California, 90808, United States
Investigational Site

San Jose, California, 95117, United States
Investigational Site

Torrance, California, 90505, United States
Investigational Site

Normal, Illinois, 61761, United States
Investigational Site

Kansas City, Missouri, 66160, United States
Investigational Site

Edmond, Oklahoma, 73034, United States
Investigational Site

Philadelphia, Pennsylvania, 19140, United States
Investigational Site

Pittsburgh, Pennsylvania, 15241, United States
Investigational Site

Bradford, West Yorkshire, BD9 6RJ, United Kingdom
Investigational Site

Manchester, M23 9QZ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.